Timothy R Rebbeck
Professor

Timothy R Rebbeck

Vincent L. Gregory, Jr. Professor of Cancer Prevention

Epidemiology

timothy_rebbeck@dfci.harvard.edu


Overview

Dr. Rebbeck is the Vincent L. Gregory, Jr. Professor of Cancer Prevention at the Harvard TH Chan School of Public Health and Professor of Medical Oncology at the Dana-Farber Cancer Institute. Dr. Rebbeck’s research focuses on the etiology and prevention of cancer, with an emphasis on cancers with a genetic etiology and those that are associated with disparities in incidence or mortality by race. He has directed multiple large molecular epidemiologic studies and international consortia that have been used to identify and characterize genes involved in cancer etiology, understand the relationship of allelic variation with biochemical or physiological traits, explore interactions of inherited and somatic genomic variation with epidemiological risk factors.

Prostate Cancer
Dr. Rebbeck’s research focuses on the causes and prevention of prostate cancer and cancer disparities using two research studies:
• “Study of Clinical Outcomes, Risk and Ethnicity” (SCORE) is an ongoing, large-scale epidemiological study to evaluate risk factors for prostate cancer, with a focus on genetic markers of etiology and outcomes in African, African American, and European American men. This research began in 1994 as part of Dr. Rebbeck’s Cancer Prevention Academic Award from the NCI, and has since grown to include studies of prostate cancer outcomes as well as etiology.
• “Men of African Descent and Carcinoma of the Prostate” (MADCaP) involves 28 centers and over 15,000 men of African descent in North America, the Caribbean, Europe, and Africa to address the global epidemic of prostate cancer in the African diaspora. As a part of this work, Dr. Rebbeck received the 2011 Landon Award for International Research for the development of this consortium and its research, and was named a Fulbright Specialist to develop cancer research centers of excellence in Africa in the period 2011-2016.

Genetic Susceptibility: Dr. Rebbeck has used the SCORE and MADCaP studies to evaluate the role of inherited genetic susceptibility in prostate cancer. His work has examined the role of genes involved in inherited susceptibility to prostate cancer, including those that regulate the metabolism of environmental carcinogens and steroid hormones in prostate cancer etiology. These genes include the HPC2 gene found on Chromosome 17, and hormone metabolism genes including cytochromes P450 (e.g. CYP3A4), androgen metabolism genes (e.g., 5-alpha reductase type II). The relationship of each of the candidate genes and of multiple candidate genes and the occurrence or age of onset of prostate cancer examined. Endogenous and/or exogenous exposures and the interaction of multiple candidate genes, environments, and exposures have been examined. His contributions in this area include the discovery of one of the first genetic loci associated with aggressive prostate cancer (Rebbeck et al., JNCI, 1998, Jaffe et al. Cancer Research, 2000). He has since identified other loci associated with prostate cancer, including validation of these loci in African descent populations (Chang et al. Cancer Epi Biom Prev 2011). He has also contributed SCORE and MADCaP data and expertise to numerous prostate cancer GWAS studies. In recognition of this research, Dr. Rebbeck was awarded the Prostate Cancer Research Award by Association for the Cure of Cancer of the Prostate (CaPCURE).

Multilevel Studies: Prostate cancer etiology and outcomes are a consequence of both biological and non-biological events. Using the SCORE database, Dr. Rebbeck has developed studies that integrate genetic, biological, individual, and neighborhood-level data to better understand the complex, multifactorial effects that influence prostate cancer. Ongoing research includes the contextual effects of neighborhood-level effects (i.e., a surrogate for lifestyle, demographics, and exposure) on the relationship of genetic susceptibility and prostate cancer outcomes (Rebbeck et al. Cancer Epi Biom Prev 2010). Using the MADCaP consortium, Dr. Rebbeck has developed national collaborative studies of the effect of genes and environments on prostate cancer outcomes. In part, this work will elucidate the biological and non-biological reasons for the disparity in prostate cancer etiology and outcomes. Dr. Rebbeck’s work currently focuses on the role of environmental stressors on telomere function, and the role of stress and telomere metrics on prostate cancer risk and outcomes. This work involves a national consortium of centers that have collected common data on neighborhood, individual, and biological measures of stress and stress response.

Biomarkers of Outcome: Developing research by Dr. Rebbeck uses ongoing prospective follow-up in the SCORE study case-cohort and the MADCaP study to evaluate factors that predict aggressive disease and unfavorable outcomes using genotypes, tumor biomarkers, and clinical information. In particular, this work involves evaluation of African descent men, who have the most unfavorable clinical outcomes of any group after a prostate cancer diagnosis. Dr. Rebbeck has developed collaborations with Dr. Kosj Yamoah (Thomas Jefferson University), Dr. Edward Schaeffer (Johns Hopkins University), and GenomeDx to develop molecular signatures of prostate cancer aggressiveness and outcome. This work asks whether molecular signatures provide additional predictive value beyond clinical parameters for prostate cancer outcomes in African descent men.

Hereditary Cancer
Dr. Rebbeck has also led studies of BRCA1 or BRCA2 mutations to understand breast, ovarian, and prostate cancer risk and precision prevention interventions that may reduce that risk. Dr. Rebbeck has led a number of international consortia including the following:

• “Prevention and Observation of Surgical Endpoints” (PROSE) is a multicenter international prospective cohort study of the clinical efficacy of cancer prevention strategies, which has led to the current clinical management and prevention recommendations for women with these mutations.
• “ BRCA1/2 International Diversity by Geography and Ethnicity (BRIDGE) is an international consortium, an arm of the CIMBA consortium, the worldwide consortium studying carriers of BRCA1 and BRCA2 mutations.

Cancer Prevention: Dr. Rebbeck has contributed to the clinical management of risk in BRCA1/2 mutation carriers by publication of research that demonstrates that risk-reducing salpingo oophorectomy (RRSO) and risk-reducing mastectomy (RRM) lead to lower breast and ovarian cancer risk (Rebbeck et al. NEJM 2002, Domchek et al. JAMA 2010) as well as reduction in mortality (Domchek et al. Lancet Oncology 2006). This series of papers has changed the clinical practice of cancer prevention in BRCA1/2 mutation carriers, such that women are currently recommended to undergo RRSO as the primary means of ovarian cancer prevention. Dr. Rebbeck’s work also demonstrated that this surgery also reduces breast cancer risk, and that post-RRSO hormone replacement therapy may be used for a short period without adding undue cancer risk in this population. Dr. Rebbeck has also shown that RRM is associated with breast cancer risk reduction, but that this surgical approach should be undertaken cautiously, as other means of breast cancer risk reduction are available.

Modification of Cancer Risks: Cancer risks among women who have inherited a BRCA1/2 mutation are the result of the complex interactions of many factors, including genes at other loci and exposures. Dr. Rebbeck has evaluated the role of other genes, including those that encode proteins that interact with BRCA1 and/or BRCA2 (Rebbeck et al. Cancer Research 2009, 2011). Additional modifier genes under study include those associated with telomere function. He has also evaluated the most definitive summary evidence for non-genetic modifiers of cancer risk in this population (Friebel et al., JNCI, 2014). Finally, in conjunction with the CIMBA consortium, he has shown that there is a strong relationship of the type, function, or location of BRCA1 or BRCA2 mutation with cancer risks (Rebbeck et al. JAMA 2015). This information can be used to refine cancer risk estimates in women with BRCA1/2 mutations and inform improved decision-making of preventive strategies.

Risks in Underrepresented Populations: The worldwide CIMBA consortium includes over 45,000 BRCA1/2 mutation carriers. However, less than 4% of these are non-White. Dr. Rebbeck has established the international BRIDGE study to specifically address cancer risk and prevention in under-represented populations.

Contributions to Academic Initiatives
In addition to his research activities, Dr. Rebbeck leads a number of initiatives on the Harvard Campus. He serves as Associate Director for Equity and Engagement in the Dana-Farber / Harvard Cancer Center and Co-Director for the Collective Impact Program of Harvard Catalyst. In this role he leads activities that determine needs and priorities for diseases and conditions that can be addressed by research. In particular, he oversees the development and implementation of research that addresses cancer needs in Massachusetts. He also oversees a team of individuals who ensure that this research engages with and impacts on relevant communities.


Bibliography

Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium.

Jordan SJ, Na R, Weiderpass E, Adami HO, Anderson KE, van den Brandt PA, Brinton LA, Chen C, Cook LS, Doherty JA, Du M, Friedenreich CM, Gierach GL, Goodman MT, Krogh V, Levi F, Lu L, Miller AB, McCann SE, Moysich KB, Negri E, Olson SH, Petruzella S, Palmer JR, Parazzini F, Pike MC, Prizment AE, Rebbeck TR, Reynolds P, Ricceri F, Risch HA, Rohan TE, Sacerdote C, Schouten LJ, Serraino D, Setiawan VW, Shu XO, Sponholtz TR, Spurdle AB, Stolzenberg-Solomon RZ, Trabert B, Wentzensen N, Wilkens LR, Wise LA, Yu H, La Vecchia C, De Vivo I, Xu W, Zeleniuch-Jacquotte A, Webb PM.

Int J Cancer. 2021 May 01. 148(9):2068-2078. PMID: 33105052


News

Exploring the decrease in U.S. cancer deaths

A decline in cancer deaths helped boost overall life expectancy in the U.S. in 2018, according to federal data. Epidemiologist Timothy Rebbeck discussed the trend in a February 21, 2020 Q&A in the Harvard Gazette. Rebbeck, Vincent L.…

Cancer symposium looks at new diagnostics for early detection

February 12, 2020 – Timothy Rebbeck kicked off the second annual Zhu Family Center for Global Cancer Prevention symposium on an optimistic note. “U.S. cancer rates have dropped dramatically. In 2016-2017, we saw the largest single-year decline in…

U.S. sees largest single-year drop in cancer death rate

Between 2016 and 2017, the U.S. cancer death rate dropped 2.2%, according to new data from the American Cancer Society. The drop marks the largest single-year decline ever recorded. Among the factors attributed to the decline are reduced…